Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.